Syros Pharmaceuticals Inc. (NASDAQ:SYRS) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Tuesday.

According to Zacks, “Syros Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on treatments for cancer and immune-mediated diseases as well as building a pipeline of gene control medicines. The company’s product pipeline includes SY-1425, a selective RARa agonist for genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia and relapsed high-risk myelodysplastic syndrome and SY-1365, a selective CDK7 inhibitor for acute leukemia which is in preclinical stage. Syros Pharmaceuticals, Inc. is based in Cambridge, Massachusetts. “

Other equities research analysts have also recently issued research reports about the stock. Piper Jaffray Cos. set a $20.00 price objective on shares of Syros Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, November 14th. HC Wainwright reaffirmed a “hold” rating and set a $10.00 price objective on shares of Syros Pharmaceuticals in a research report on Friday, September 9th. Cann initiated coverage on shares of Syros Pharmaceuticals in a research report on Monday. They set an “outperform” rating and a $28.00 price objective for the company. Finally, Wedbush reaffirmed an “outperform” rating and set a $18.00 price objective on shares of Syros Pharmaceuticals in a research report on Monday, November 14th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $19.60.

Analyst Recommendations for Syros Pharmaceuticals (NASDAQ:SYRS)

Shares of Syros Pharmaceuticals (NASDAQ:SYRS) opened at 13.33 on Tuesday. The firm’s market cap is $311.66 million. Syros Pharmaceuticals has a 12 month low of $8.16 and a 12 month high of $21.50. The stock’s 50 day moving average is $13.48 and its 200 day moving average is $13.08.

Syros Pharmaceuticals (NASDAQ:SYRS) last released its quarterly earnings results on Monday, November 14th. The company reported ($0.65) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.54) by $0.11. Analysts forecast that Syros Pharmaceuticals will post ($4.03) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Zacks Investment Research Downgrades Syros Pharmaceuticals Inc. (SYRS) to Sell” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another publication, it was stolen and reposted in violation of international trademark and copyright law. The legal version of this article can be read at https://www.thecerbatgem.com/2016/11/29/zacks-investment-research-downgrades-syros-pharmaceuticals-inc-syrs-to-sell.html.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Baker BROS. Advisors LP bought a new position in Syros Pharmaceuticals during the third quarter worth approximately $2,836,000. AWM Investment Company Inc. bought a new position in Syros Pharmaceuticals during the third quarter worth approximately $660,000. Morgan Stanley bought a new position in Syros Pharmaceuticals during the third quarter worth approximately $469,000. Spark Investment Management LLC bought a new position in Syros Pharmaceuticals during the third quarter worth approximately $160,000. Finally, California State Teachers Retirement System bought a new position in Syros Pharmaceuticals during the third quarter worth approximately $137,000. 54.56% of the stock is owned by hedge funds and other institutional investors.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on developing treatments for cancer and immune-mediated diseases. The Company’s gene control platform focuses on identifying gene control targets linked to genomically defined patient populations, and drugging gene control targets.

5 Day Chart for NASDAQ:SYRS

Receive News & Stock Ratings for Syros Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.